NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions.
1 - 45 . (canceled)
46 . A method for treating a NSAID induced enteropathy in a human undergoing NSAID administration comprising administering to the human from 400 mg to 800 mg rifaximin once, twice, three times, or four times a day for a period of two weeks or more in combination with a gastric acid inhibitor.
47 . The method of claim 46 , wherein the NSAID induced enteropathy is a severe enteropathy.
48 . The method of claim 46 , wherein the NSAID induced enteropathy is associated with small bowel lesions of Categories 3 and 4.
49 . The method of claim 46 , wherein the NSAID administration has a duration of at least two weeks.
50 . The method of claim 46 , wherein the gastric acid inhibitor is a proton pump inhibitor.
51 . The method of claim 46 , wherein the gastric acid inhibitor is selected from lansoprazole, ilaprazole, omeprazole, tenatoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, leminoprazole and nepaprazole.
52 . The method of claim 46 , wherein the gastric acid inhibitor is omeprazole.
53 . The method of claim 46 , wherein the NSAID is selected from diclofenac, ketoprofen, naproxen, ibuprofen, and mixtures thereof.
54 . The method of claim 46 , wherein the NSAID is diclofenac.
55 . The method of claim 46 , wherein the hemoglobin level of the human undergoing NSAID administration is increased following the administration of rifaximin.
56 . The method of claim 46 , wherein the intestinal myeloperoxidase (MPO) levels of the human undergoing NSAID administration is decreased following the administration of rifaximin.
57 . The method of claim 46 , wherein the NSAID induced enteropathy is associated with small bowel lesions, wherein said lesions are reduced following the administration of rifaximin.